Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: IMARC | PRODUCT CODE: 1378836

Cover Image

PUBLISHER: IMARC | PRODUCT CODE: 1378836

Benign Prostatic Hyperplasia Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

PUBLISHED:
PAGES: 144 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 2499
PDF & Excel (5 User License)
USD 3499
PDF & Excel (Corporate License)
USD 4499

Add to Cart

Abstract

The global benign prostatic hyperplasia treatment market size reached US$ 11.3 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 15.5 Billion by 2028, exhibiting a growth rate (CAGR) of 5.4% during 2022-2028.

Benign prostatic hyperplasia (BPH) or benign prostatic hypertrophy refers to the non-cancerous enlargement of the prostate gland that causes blockage in the urethra. This condition causes difficulties in urine retention, bladder stones, incontinence due to overfilling, increased sensitivity of the bladder and infections in the urinary tract. Some of the commonly used treatment alternatives for BPH include prescription drugs, active observation or surveillance, mono drug and combined therapies, phytotherapies and minimally invasive (MI) and invasive surgeries. These surgeries are usually conducted through devices, such as resectoscopes, radiofrequency ablation devices, urology lasers, prostatic stents and implants.

The increasing prevalence of urological disorders across the globe represents one of the key factors creating a positive outlook for the market. Furthermore, the rising geriatric population, which is more susceptible to such critical ailments, is providing a boost to the market growth. Healthcare providers use alpha-blockers to manage BPH by relaxing the prostate muscles and controlling the blood pressure of the patient. In line with this, rising health consciousness and awareness among the masses regarding the available treatment alternatives are also contributing to the market growth. Additionally, various advancements, such as the development of transurethral resection of the prostate (TURP) as an effective treatment procedure, are acting as other growth-inducing factors. TURP is an endoscopic electrosurgical procedure that involves removing a portion of the prostate gland to reduce obstruction caused by the abnormal growth. Other factors, including rising healthcare expenditure capacities of individuals, along with significant improvements in the healthcare infrastructure, especially in the developing countries, are anticipated to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global benign prostatic hyperplasia treatment market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on treatment type.

Breakup by Treatment Type:

Drug Class

Alpha-Blockers

5-Alpha-reductase Inhibitors (5-ARIs)

Phosphodiesterase-5 Enzyme Inhibitors

Others

Minimally Invasive Surgeries

Transurethral Resection of the Prostate (TURP)

Transurethral Incision of the Prostate (TUIP)

Transurethral Microwave Thermotherapy (TUMT)

Robotic Surgeries

Prostatic Urethral Lifts

Others

Laser Therapy

Others

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Abbott Laboratories, Allergan Plc (AbbVie Inc.), Asahi Kasei Corporation, Astellas Pharma Inc., Boehringer Ingelheim GmbH (C.H. Boehringer Sohn AG & Ko. KG), Boston Scientific Corporation, GlaxoSmithKline Plc, Pfizer Inc., Sanofi S.A. and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report:

  • How has the global benign prostatic hyperplasia treatment market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global benign prostatic hyperplasia treatment market?
  • What are the key regional markets?
  • What is the breakup of the market based on the treatment type?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global benign prostatic hyperplasia treatment market and who are the key players?
  • What is the degree of competition in the industry?
Product Code: SR112023A2898

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Benign Prostatic Hyperplasia Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Treatment Type

  • 6.1 Drug Class
    • 6.1.1 Market Trends
    • 6.1.2 Major Types
      • 6.1.2.1 Alpha-Blockers
      • 6.1.2.2 5-Alpha-reductase Inhibitors (5-ARIs)
      • 6.1.2.3 Phosphodiesterase-5 Enzyme Inhibitors
      • 6.1.2.4 Others
    • 6.1.3 Market Forecast
  • 6.2 Minimally Invasive Surgeries
    • 6.2.1 Market Trends
    • 6.2.2 Major Types
      • 6.2.2.1 Transurethral Resection of the Prostate (TURP)
      • 6.2.2.2 Transurethral Incision of the Prostate (TUIP)
      • 6.2.2.3 Transurethral Microwave Thermotherapy (TUMT)
      • 6.2.2.4 Robotic Surgeries
      • 6.2.2.5 Prostatic Urethral Lifts
      • 6.2.2.6 Others
    • 6.2.3 Market Forecast
  • 6.3 Laser Therapy
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Region

  • 7.1 North America
    • 7.1.1 United States
      • 7.1.1.1 Market Trends
      • 7.1.1.2 Market Forecast
    • 7.1.2 Canada
      • 7.1.2.1 Market Trends
      • 7.1.2.2 Market Forecast
  • 7.2 Asia Pacific
    • 7.2.1 China
      • 7.2.1.1 Market Trends
      • 7.2.1.2 Market Forecast
    • 7.2.2 Japan
      • 7.2.2.1 Market Trends
      • 7.2.2.2 Market Forecast
    • 7.2.3 India
      • 7.2.3.1 Market Trends
      • 7.2.3.2 Market Forecast
    • 7.2.4 South Korea
      • 7.2.4.1 Market Trends
      • 7.2.4.2 Market Forecast
    • 7.2.5 Australia
      • 7.2.5.1 Market Trends
      • 7.2.5.2 Market Forecast
    • 7.2.6 Indonesia
      • 7.2.6.1 Market Trends
      • 7.2.6.2 Market Forecast
    • 7.2.7 Others
      • 7.2.7.1 Market Trends
      • 7.2.7.2 Market Forecast
  • 7.3 Europe
    • 7.3.1 Germany
      • 7.3.1.1 Market Trends
      • 7.3.1.2 Market Forecast
    • 7.3.2 France
      • 7.3.2.1 Market Trends
      • 7.3.2.2 Market Forecast
    • 7.3.3 United Kingdom
      • 7.3.3.1 Market Trends
      • 7.3.3.2 Market Forecast
    • 7.3.4 Italy
      • 7.3.4.1 Market Trends
      • 7.3.4.2 Market Forecast
    • 7.3.5 Spain
      • 7.3.5.1 Market Trends
      • 7.3.5.2 Market Forecast
    • 7.3.6 Russia
      • 7.3.6.1 Market Trends
      • 7.3.6.2 Market Forecast
    • 7.3.7 Others
      • 7.3.7.1 Market Trends
      • 7.3.7.2 Market Forecast
  • 7.4 Latin America
    • 7.4.1 Brazil
      • 7.4.1.1 Market Trends
      • 7.4.1.2 Market Forecast
    • 7.4.2 Mexico
      • 7.4.2.1 Market Trends
      • 7.4.2.2 Market Forecast
    • 7.4.3 Others
      • 7.4.3.1 Market Trends
      • 7.4.3.2 Market Forecast
  • 7.5 Middle East and Africa
    • 7.5.1 Market Trends
    • 7.5.2 Market Breakup by Country
    • 7.5.3 Market Forecast

8 SWOT Analysis

  • 8.1 Overview
  • 8.2 Strengths
  • 8.3 Weaknesses
  • 8.4 Opportunities
  • 8.5 Threats

9 Value Chain Analysis

10 Porters Five Forces Analysis

  • 10.1 Overview
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Degree of Competition
  • 10.5 Threat of New Entrants
  • 10.6 Threat of Substitutes

11 Price Analysis

12 Competitive Landscape

  • 12.1 Market Structure
  • 12.2 Key Players
  • 12.3 Profiles of Key Players
    • 12.3.1 Abbott Laboratories
      • 12.3.1.1 Company Overview
      • 12.3.1.2 Product Portfolio
      • 12.3.1.3 Financials
      • 12.3.1.4 SWOT Analysis
    • 12.3.2 Allergan plc (AbbVie Inc.)
      • 12.3.2.1 Company Overview
      • 12.3.2.2 Product Portfolio
      • 12.3.2.3 Financials
      • 12.3.2.4 SWOT Analysis
    • 12.3.3 Asahi Kasei Corporation
      • 12.3.3.1 Company Overview
      • 12.3.3.2 Product Portfolio
      • 12.3.3.3 Financials
      • 12.3.3.4 SWOT Analysis
    • 12.3.4 Astellas Pharma Inc.
      • 12.3.4.1 Company Overview
      • 12.3.4.2 Product Portfolio
      • 12.3.4.3 Financials
      • 12.3.4.4 SWOT Analysis
    • 12.3.5 Boehringer Ingelheim GmbH (C.H. Boehringer Sohn AG & Ko. KG)
      • 12.3.5.1 Company Overview
      • 12.3.5.2 Product Portfolio
      • 12.3.5.3 SWOT Analysis
    • 12.3.6 Boston Scientific Corporation
      • 12.3.6.1 Company Overview
      • 12.3.6.2 Product Portfolio
      • 12.3.6.3 Financials
      • 12.3.6.4 SWOT Analysis
    • 12.3.7 GlaxoSmithKline Plc
      • 12.3.7.1 Company Overview
      • 12.3.7.2 Product Portfolio
      • 12.3.7.3 Financials
      • 12.3.7.4 SWOT Analysis
    • 12.3.8 Pfizer Inc.
      • 12.3.8.1 Company Overview
      • 12.3.8.2 Product Portfolio
      • 12.3.8.3 Financials
      • 12.3.8.4 SWOT Analysis
    • 12.3.9 Sanofi S.A.
      • 12.3.9.1 Company Overview
      • 12.3.9.2 Product Portfolio
      • 12.3.9.3 Financials
      • 12.3.9.4 SWOT Analysis
    • 12.3.10 Teva Pharmaceutical Industries Ltd.
      • 12.3.10.1 Company Overview
      • 12.3.10.2 Product Portfolio
      • 12.3.10.3 Financials
      • 12.3.10.4 SWOT Analysis
Product Code: SR112023A2898

List of Figures

  • Figure 1: Global: Benign Prostatic Hyperplasia Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: Benign Prostatic Hyperplasia Treatment Market: Breakup by Treatment Type (in %), 2022
  • Figure 4: Global: Benign Prostatic Hyperplasia Treatment Market: Breakup by Region (in %), 2022
  • Figure 5: Global: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 6: Global: Benign Prostatic Hyperplasia Treatment (Drug Class) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 7: Global: Benign Prostatic Hyperplasia Treatment (Drug Class) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 8: Global: Benign Prostatic Hyperplasia Treatment (Minimally Invasive Surgeries) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 9: Global: Benign Prostatic Hyperplasia Treatment (Minimally Invasive Surgeries) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 10: Global: Benign Prostatic Hyperplasia Treatment (Laser Therapy) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 11: Global: Benign Prostatic Hyperplasia Treatment (Laser Therapy) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 12: Global: Benign Prostatic Hyperplasia Treatment (Other Treatment Types) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 13: Global: Benign Prostatic Hyperplasia Treatment (Other Treatment Types) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 14: North America: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 15: North America: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 16: United States: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 17: United States: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 18: Canada: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 19: Canada: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 20: Asia Pacific: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 21: Asia Pacific: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 22: China: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 23: China: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 24: Japan: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 25: Japan: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 26: India: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 27: India: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 28: South Korea: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 29: South Korea: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 30: Australia: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 31: Australia: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 32: Indonesia: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 33: Indonesia: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 34: Others: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 35: Others: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 36: Europe: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 37: Europe: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 38: Germany: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 39: Germany: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 40: France: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 41: France: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 42: United Kingdom: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 43: United Kingdom: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 44: Italy: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 45: Italy: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 46: Spain: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 47: Spain: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 48: Russia: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 49: Russia: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 50: Others: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 51: Others: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 52: Latin America: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 53: Latin America: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 54: Brazil: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 55: Brazil: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 56: Mexico: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 57: Mexico: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 58: Others: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 59: Others: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 60: Middle East and Africa: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 61: Middle East and Africa: Benign Prostatic Hyperplasia Treatment Market Forecast: Breakup by Country (in %), 2022
  • Figure 62: Middle East and Africa: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 63: Global: Benign Prostatic Hyperplasia Treatment Industry: SWOT Analysis
  • Figure 64: Global: Benign Prostatic Hyperplasia Treatment Industry: Value Chain Analysis
  • Figure 65: Global: Benign Prostatic Hyperplasia Treatment Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Benign Prostatic Hyperplasia Treatment Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Benign Prostatic Hyperplasia Treatment Market Forecast: Breakup by Treatment Type (in Million US$), 2023-2028
  • Table 3: Global: Benign Prostatic Hyperplasia Treatment Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 4: Global: Benign Prostatic Hyperplasia Treatment Market: Competitive Structure
  • Table 5: Global: Benign Prostatic Hyperplasia Treatment Market: Key Players
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!